May 21, 2020
EDIT: Removed press release
EDIT: Juvenescence put out a press release in error on May 21st, and it has been removed.
Pharmaceuticals, Biotechnology and Life Sciences
Category: Regions
May 21, 2020
scPharmaceuticals in pricing of public offering of common stock of about $50.0 million
BURLINGTON, Mass.–(BUSINESS WIRE)–$SCPH #FUROSCIX–scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential…
May 20, 2020
Virpax scores at the pre-IND meeting with FDA on Epoladerm for Knee Osteoarthritis
Virpax Pharmaceuticals has successfully completed a pre-Investigational New Drug (IND) Application meeting with the U.S. Food and Drug Administration (FDA)…
May 18, 2020
ChemoCentryx on track to check with FDA for Avacopan, in the treatment of ANCA vasculitis
Thomas J. Schall, Ph.D., President and Chief Executive Officer of ChemoCentryx, said that the company will release topline data from the LUMINA-2 study of CCX140.
May 18, 2020
Moderna’s coronavirus vaccine candidate expected in Phase 3 study in July
Moderna said that after two doses all participants evaluated to date across the 25 µg and 100 µg dose cohorts…
May 18, 2020
Leinco, VUMC making antibodies for fast COVID-19 test
Leinco Technologies and Vanderbilt University Medical Center (VUMC) have agreed to scale up production of its most promising antibodies for development of a rapid, point of care COVID-19 diagnostic test.
May 18, 2020
Alvotech welcomes deputy CEO in Iceland
Alvotech has named Tanya Zharov as deputy chief executive officer in Iceland to oversee Icelandic operations and administration, including the Reykjavik site leadership team, human resources, business operations, shared services and facilities.
May 18, 2020
FDA approves Genentech’s Tecentriq for certain metastatic lung cancer patients
– Tecentriq’s fourth indication in metastatic non-small cell lung cancer and fifth indication in lung cancer overall – – Approval…
May 18, 2020
Avacopan new focus for VFMCRP and ChemoCentryx, CCX140 won’t move forward in FSGS
In the study, CCX140 did not demonstrate a meaningful reduction in proteinuria relative to the control group after 12 weeks of blinded treatment.
May 16, 2020
Moderna’s director Dr. Moncef Slaoui to oversee the White House’s operation Warp Speed initiative
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create…